ENहिन्दी soon
Home/India/Blog/How much weight
INIndia Medicines

How much weight do people lose on Ozempic or Mounjaro? What the trials found

Ozempic before and after, in numbers rather than photos. Trial averages for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), beside the dummy-injection groups. Plus who lost little, the side effects and the regain.

GLP Guidebook teamPublished 5 Oct 202613 min read38 sourcesWritten from published sources

Written for India. Reading from the US? US versionComing soon

The short answer

In the big trials, adults without diabetes lost about 15% on semaglutide 2.4 mg, the Wegovy dose. Tirzepatide (Mounjaro) gave 15% to 21%. Both trials ran about 16 months, and dummy injections gave 2% to 3%. Ozempic's lower diabetes doses gave about 4 to 6 kg, against about 1 kg on a dummy. Most people regained weight after stopping.

Key takeaways

  • In the STEP 1 trial, adults without diabetes lost 15% of their weight on semaglutide 2.4 mg over 68 weeks, against 2% on a dummy injection.1
  • On semaglutide 2.4 mg, 44% felt sick (nausea), against 16% on the dummy injection.2
  • In SURMOUNT-1, tirzepatide gave average losses of 15% to 21% over 72 weeks, and 4% to 7% stopped because of side effects.3
  • People with type 2 diabetes lost less in STEP 2, about 10% on semaglutide, and about 1 in 3 of them lost under 5% of their weight.5,2
  • One year after stopping semaglutide in the STEP 1 extension, people had regained two-thirds of the weight they had lost.15
On this page
  1. How much weight did people lose in the big trials?
  2. How do the trials compare?
  3. Do people with type 2 diabetes lose as much?
  4. What do trials in Asian and Indian people show?
  5. How many people lose less than 5%?
  6. What happens after people stop?
  7. Do any weight-loss pills actually work as well?
  8. Questions people ask
  9. How we researched this

How much weight did people lose in the big trials?

Adults without diabetes lost about 15% of their weight on semaglutide 2.4 mg, the Wegovy dose, and 15% to 21% on tirzepatide.

Before you go further
  • These are prescription-only medicines in India. A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.24,37 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.38 More in Do you need a prescription for GLP‑1 medicines in India?
  • Every benefit below comes with side effects. The full list is in Guide 5: side effects and risks.
  • Select batches of three generic semaglutide brands were recalled in July 2026, so check your batch.25
  • No result is promised. The numbers here are trial averages, and CDSCO warns against promotions that guarantee weight-loss outcomes.26

Ozempic is the same medicine, semaglutide, at lower diabetes doses of 0.5 to 2 mg. In its US-label trials, those doses gave about 4 to 6 kg.7 In the 30-week trial, the dummy group lost about 1 kg.7 The Ozempic results are further down, and how the brands relate is in Is semaglutide the same as Ozempic?

The 15% figures come from two large trials with a dummy injection (placebo) group. Each ran about 16 months (68 and 72 weeks).1,3

In STEP 1, 1,961 adults without diabetes took weekly semaglutide 2.4 mg or a dummy for 68 weeks.1 Everyone also got advice on eating less and moving more.2

The semaglutide group lost 15% of their weight on average, and the dummy group lost 2%.1 In kilos, that was 15 kg against 3 kg.1

In SURMOUNT-1, 2,539 adults without diabetes took tirzepatide at 5, 10 or 15 mg, or a dummy, for 72 weeks.3 Average losses were 15%, 20% and 21% by dose, against 3% on the dummy.3 At the two higher doses, half or more lost at least 20% of their weight.3

Both trials took adults with a BMI of 30 or more, or 27 or more with a weight-related condition.1,3 Those are Western cut-offs.

The 2009 Indian consensus puts obesity at a BMI of 25 or more.29 You can check your own numbers with the BMI and waist tool.

What the averages mean for one person (80 kg example)

For an 80 kg person, a 15% loss is about 12 kg. The dummy group's 2% is under 2 kg.1 At the top tirzepatide dose, 21% is about 17 kg, against about 2.5 kg on the dummy.3

Those are averages, and people spread widely around them. In STEP 1, about half lost 15% or more, but about 1 in 6 lost under 5%.2

What it cost in side effects

Most side effects were in the stomach and gut. On semaglutide 2.4 mg, 44% felt sick (nausea) and 24% vomited, against 16% and 6% on the dummy.2 On tirzepatide 15 mg, 28% had nausea, against 8%.4

Most of these effects were mild to moderate and came during or just after the dose steps.17 Still, 4% to 7% on tirzepatide stopped because of side effects, against 3% on the dummy.3 In STEP 1, 4.5% stopped because of stomach effects, against 0.8%.1

The weight loss barely depended on feeling sick. Across STEP 1 to 3, people lost similar weight with or without stomach side effects.17 Under 1 percentage point of the extra loss came through those side effects.17

RisksThe risks, in brief
  • Stomach effects are common. Nausea 44% vs 16%, diarrhoea 30% vs 16%, vomiting 24% vs 6% (semaglutide 2.4 mg vs dummy, US label).2
  • Pancreatitis. Inflammation of the pancreas: stomach pain that is severe or won't go away, sometimes spreading to the back.2
  • Gallbladder problems. Gallstones were reported by 1.6% on semaglutide, against 0.7% on the dummy.2
  • Dehydration from vomiting or diarrhoea can damage the kidneys.2
  • Thyroid warning. Ruled out by the US label for anyone with a personal or family history of MTC (a rare thyroid cancer) or MEN 2; tell your doctor if this applies. Not in pregnancy.2
Full detail in Guide 5: Side effects and risks →
Get help now: call 112 for stomach pain that is severe or won't go away, especially if it spreads to your back.2

How do the trials compare?

The table puts each trial's medicine group beside its own dummy group, because comparing one trial with another can mislead.

Each trial had different people, doses and lengths. So read each row on its own, not against the row above it.

TrialWho and how longAverage loss on the medicineAverage loss on the dummyLost under 5% (medicine group)Stopped because of side effects (medicine vs dummy)
STEP 11,21,961 adults without diabetes, 68 weeksSemaglutide 2.4 mg: 15%2%17%4.5% vs 0.8% (stomach effects)
SURMOUNT-13,42,539 adults without diabetes, 72 weeksTirzepatide 5 to 15 mg: 15% to 21%3%9% to 15%4% to 7% vs 3%
STEP 25,21,210 adults with type 2 diabetes, 68 weeksSemaglutide 2.4 mg: 10%3%33%Not in the summary we could open; stomach effects 64% vs 34%
SURMOUNT-26,4938 adults with type 2 diabetes, 72 weeksTirzepatide 10 or 15 mg: 13% to 15%3%17% to 21%Under 5%
STEP 68,2401 adults in Japan and South Korea, 68 weeksSemaglutide 2.4 mg: 13%2%16%3% vs 1%
SURMOUNT-J9225 Japanese adults without diabetes, 72 weeksTirzepatide 10 or 15 mg: 16 to 21 points more than the dummyNot given in the summary4% to 6% (on-treatment)0% to 1% vs 4%
SURMOUNT-CN10210 Chinese adults without diabetes, 52 weeksTirzepatide 10 or 15 mg: 14% to 18%2%12% to 14%Under 5%
Delhi hospital records (not a trial)12150 adults, about half with type 2 diabetes, median 6.5 monthsSemaglutide or tirzepatide: median 8%No dummy group27% (46% of those with diabetes)No severe effects that forced a stop; nausea 31%

Average loss is the share of starting body weight, rounded. "Lost under 5%" comes from the US labels' tables of everyone randomised, or else the trial summary. SURMOUNT-J counts only people who stayed on treatment (on-treatment). Opened 5 Oct 2026.

Do people with type 2 diabetes lose as much?

No. In trials of people with type 2 diabetes, the same medicines gave smaller losses, about 10% on semaglutide and 13% to 15% on tirzepatide.

STEP 2 enrolled 1,210 adults with type 2 diabetes and a BMI of 27 or more.5 After 68 weeks, semaglutide 2.4 mg gave a 10% loss, against 3% on the dummy.5 About 1 in 3 on semaglutide lost under 5%.2

SURMOUNT-2 tested tirzepatide in 938 adults with type 2 diabetes for 72 weeks.6 Losses were 13% on 10 mg and 15% on 15 mg, against 3% on the dummy.6 Between 17% and 21% of the tirzepatide groups lost under 5%.4

Side effects came with these results too. In STEP 2, 64% on semaglutide 2.4 mg reported stomach effects, against 34% on the dummy.5 In SURMOUNT-2, fewer than 5% stopped tirzepatide because of side effects.6

In India, Ozempic is the diabetes brand. It launched in India in December 2025 for type 2 diabetes.18 The STEP weight trials used semaglutide 2.4 mg, the Wegovy dose, which launched in India in June 2025.20 Mounjaro (tirzepatide) is sold in India for diabetes and obesity.19

A 30-week trial of Ozempic's diabetes doses found 4 kg lost on 0.5 mg and 5 kg on 1 mg.7 The dummy group lost 1 kg.7

In a 40-week trial, 2 mg gave 6.4 kg against 5.6 kg on 1 mg.7 That gap was too small to be sure of.7

On those doses, 16% to 20% had nausea, against 6% on the dummy.7 Between 3% and 4% stopped because of stomach effects, against 0.4%.7

What do trials in Asian and Indian people show?

Trials in East Asian adults found losses close to the global trials, but we found no published India-only trial with a dummy group.

STEP 6 enrolled 401 adults in Japan and South Korea, a quarter of them with type 2 diabetes.8,2 Semaglutide 2.4 mg gave a 13% loss over 68 weeks, against 2% on the dummy.8 Stomach effects hit 59%, against 30%, and 3% stopped for side effects, against 1%.8

SURMOUNT-J tested tirzepatide in 225 Japanese adults without diabetes for 72 weeks.9 Losses were 16 and 21 percentage points more than the dummy, on 10 mg and 15 mg.9 Side effects were reported by 84% to 86% on tirzepatide and 69% on the dummy, mostly stomach effects.9

SURMOUNT-CN enrolled 210 Chinese adults, starting from a BMI of 24 with a weight-related condition.10 After 52 weeks, losses were 14% on 10 mg and 18% on 15 mg, against 2% on the dummy.10 Fewer than 5% stopped because of side effects.10

Indians did take part in the global trials. STEP 1 had 13 sites in India, STEP 2 had 16 and SURMOUNT-1 had 6.11 We found no published results for the Indian participants on their own.

What Indian clinics have reported

A Delhi hospital looked back at the records of 150 adults on semaglutide or tirzepatide. Of these, 74 had type 2 diabetes.12

After a median of 6.5 months, the median loss was 8%.12 The middle half of people lost between 5% and 14%.12

People without diabetes lost 11%, against 5% for people with it.12 Nausea was reported by 31%, and diarrhoea and constipation by 25% each.12 There was no dummy group, and looking back at records is weaker evidence than a trial.12

In Lucknow, 7 centres reviewed 71 adults with type 2 diabetes after 3 months of tirzepatide.13 They lost 4.7 kg on average, about 6% of their weight.13 But 22% stopped, most often because of stomach effects or cost.13

One Indian trial compared a generic semaglutide with Wegovy in 249 adults for 24 weeks.14 Both groups lost about 14%.14 It had no dummy group, and the generic's maker, Alkem, sponsored it.14

Free toolCould a GLP-1 be an option to discuss?

Answer a few questions and see what Indian guidelines say a doctor may consider. No sign-up.

Open the check

How many people lose less than 5%?

In the trials, between about 1 in 10 and 1 in 3 people on these medicines lost under 5% of their weight.

Five percent matters because guidelines use it as a check. UK guidance says to consider stopping semaglutide if under 5% is lost after 6 months.28 India's ESI 2025 guideline suggests a 3-month trial to judge whether a medicine works and is tolerated.27

The same guideline says doctors must explain that results vary between people.27

Who lost less than 5% of their weight
Share of the medicine group, % (from the table above)
STEP trials from the US Wegovy label, SURMOUNT trials from the US Zepbound label. Delhi figures come from hospital records with no dummy group. Opened 5 Oct 2026.2,4,12

In the Delhi records, 46% of people with diabetes lost under 5%, against 11% of people without.12 On the dummy injection, 69% in STEP 1 and 66% in SURMOUNT-1 lost under 5%.2,4

What happens after people stop?

In both big trials that tested stopping, most people regained a large share of their lost weight within about a year.

The STEP 1 extension followed 327 people for a year after the 68 weeks of treatment ended.15 The semaglutide group had lost 17%, then regained 12 percentage points.15 In the authors' words, they "regained two-thirds of their prior weight loss".15

By week 120, 48% were still at least 5% below their starting weight, down from 86% at week 68.15 Most gains in blood pressure, blood sugar and blood fats also slipped back toward the start.15

SURMOUNT-4 gave everyone tirzepatide for 36 weeks, by which point they had lost 21%.16 Then half were switched to a dummy without knowing it.16 Over the next year, the switched group gained 14% while those still on tirzepatide lost another 6%.16

Only 17% of the switched group kept at least 80% of their loss, against 90% who stayed on tirzepatide.16 Before the switch, 14% had already stopped, most often because of side effects.4

What stopping involves, and how people plan for it, is in Guide 9: stopping and the long term. A deeper post on regain is What happens when you stop Ozempic or Mounjaro?.

Do any weight-loss pills actually work as well?

In trials, orlistat beat a dummy pill by about 2 to 3 kg, and the diabetes tablet Rybelsus by about 1 to 2 kg.23,31,32

Orlistat is the only pill among the obesity medicines available in India.22 Rybelsus is approved here for type 2 diabetes.21 A semaglutide tablet sold only in the US gave 14%, against 2% on a dummy.2

Each result below sits beside its own dummy group and its side effects. The trials differ in people, doses and length, so read each pill on its own.

Orlistat 120 mg (prescription)

Orlistat works in the gut. It blocks the enzymes that digest fat, so about 30% of the fat in a meal is not absorbed.30 It is one of four obesity medicines available in India.22

In an Indian trial of 80 adults, orlistat gave 4.65 kg over 24 weeks, against 2.5 kg on a dummy.23 In XENDOS, a 4-year trial of 3,305 people, it gave 5.8 kg against 3.0 kg.31 Only 52% on orlistat finished the 4 years.31

The side effects come from the fat that passes through. In year 1 of the US-label trials, 27% had oily spotting and 8% leaked stool. On the dummy, each was about 1%.30

In those trials, 8.8% stopped because of side effects, against 5.0%.30 Rare cases of severe liver injury have been reported.30

In the US, a 60 mg dose is sold without a prescription.33 The Indian pharmacy listings we checked mark the 60 mg capsule as a prescription drug.36 The full comparison is in Orlistat vs GLP-1 medicines.

Rybelsus (semaglutide tablets, for diabetes)

In India, Rybelsus is approved for type 2 diabetes.21 A 2026 Indian review says oral semaglutide is not formally approved for obesity.22

A 26-week US-label trial tested it in people with type 2 diabetes. The 7 mg dose gave 2.3 kg and 14 mg gave 3.7 kg.32 The dummy group lost 1.4 kg.32 The 7 mg gap over the dummy, 0.9 kg, was too small to be sure it was real.32

Of that trial's 703 people, 17% were Asian.32

On 14 mg, 20% had nausea, against 6% on the dummy.32 And 8% stopped because of stomach effects, against 1%.32

The 3 mg first-month dose does not control blood sugar.32 More on that dose is in What is Rybelsus 3 mg used for?

Wegovy tablets (25 mg, US)

A 25 mg semaglutide tablet is sold in the US as Wegovy tablets. In its 64-week trial, 307 adults lost 14%, against 2% on a dummy pill.2 We found no Indian approval for it for weight.22

About 1 in 4 lost under 5%, and 6.9% stopped for side effects, against 5.9%.2 Only 1% of that trial's people were Asian.2 The tablet question has its own post: Is there an Ozempic tablet?

Why are supplements and "fat burners" not on this list?

We left them out because none of our sources tested them against a dummy. In the US, the FDA says many weight-loss products sold as supplements have contained hidden prescription drugs.34

One, first flagged in 2019, still contained sibutramine when the FDA checked again in July 2026. Sibutramine can raise blood pressure and heart rate.35 Ayurvedic and homeopathic products have their own post: Do ayurvedic, Patanjali or homeopathic weight-loss medicines work?

Questions people ask

Are Ozempic before-and-after photos realistic?

A photo shows one person. In STEP 1, about half on semaglutide 2.4 mg lost 15% or more of their weight. About 1 in 6 lost under 5%.2

How much weight do people lose on Mounjaro?

In SURMOUNT-1, adults without diabetes lost 15% to 21% over 72 weeks, depending on the dose. The dummy group lost 3%. People with type 2 diabetes lost 13% to 15% in SURMOUNT-2.3,6

Do people with diabetes lose less weight on semaglutide?

Yes. In STEP 2, adults with type 2 diabetes lost 10% on semaglutide 2.4 mg. In STEP 1, adults without diabetes lost 15%.5,1

Do weight-loss pills work as well as the injections?

Not in the trials we found. Orlistat gave 4.65 kg against 2.5 kg on a dummy in an Indian trial. Rybelsus, a diabetes tablet, gave 2.3 to 3.7 kg, against 1.4 kg on a dummy. A 25 mg semaglutide tablet sold in the US gave 14%.23,32,2

What happens if someone loses less than 5%?

UK guidance says to consider stopping semaglutide if under 5% is lost after 6 months. India's ESI 2025 guideline suggests a 3-month trial to judge whether a medicine works and is tolerated.28,27

Does the weight come back after stopping Ozempic or Mounjaro?

Mostly, yes. A year after stopping semaglutide in the STEP 1 extension, people had regained two-thirds of the weight they lost. In SURMOUNT-4, people switched off tirzepatide regained 14% of their weight in a year.15,16

How we researched this

On 5 October 2026 we opened every trial summary on PubMed or Europe PMC. We read the full text where it was free. Label figures come from the US Wegovy, Zepbound and Ozempic labels, not Indian ones.

Zepbound is the US weight brand of tirzepatide, the medicine in Mounjaro. For "lost under 5%", we used the labels' tables that count everyone who was randomised, including people who stopped. We checked trial site lists on ClinicalTrials.gov to see which trials ran in India.

We could not open the full STEP 1 and STEP 2 papers. So STEP 2's rate of stopping for side effects is missing from the table. We found no published results for Indian participants alone.

For the pills, we read the US Xenical, Alli and Rybelsus labels, two orlistat trials and two FDA notices. We used no before-and-after photos or personal stories.

Before you move on

  • Trial averages were about 15% on semaglutide 2.4 mg, 15% to 21% on tirzepatide, and 2% to 3% on a dummy.
  • People with type 2 diabetes lost less, and between 1 in 10 and 1 in 3 people lost under 5%.
  • Side effects, mostly in the stomach, came with the benefit, and 4% to 7% on tirzepatide stopped because of them.
  • Most of the weight came back within a year of stopping.
Stopping and the long termSide effects and risksI'm considering it for my weight

More from the India blog

INIndiaMedicinesMounjaro vs Ozempic: how do they differ in India? INIndiaComing soonWhat happens when you stop Ozempic or Mounjaro? INIndiaComing soonMounjaro side effects: what the trials and the label say
About GLP Guidebook

The monthly India update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write

Was this post easy to understand?

Sources

  1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989–1002. DOI · PMID 33567185
  2. Novo Nordisk. Wegovy (semaglutide) prescribing information, revised 06/2026. US label, not the Indian one: used for its intention-to-treat tables, side-effect rates and warnings. PDF
  3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205–16. DOI · PMID 35658024
  4. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. US label: same medicine as Mounjaro; used for its SURMOUNT tables and side-effect rates. PDF
  5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971–84. DOI · PMID 33667417
  6. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402:613–26. DOI · PMID 37385275
  7. Novo Nordisk. Ozempic (semaglutide) prescribing information, revised 05/2026. US label: weight results at diabetes doses. PDF
  8. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes Endocrinol 2022;10:193–206. DOI · PMID 35131037
  9. Kadowaki T et al. Once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J). Lancet Diabetes Endocrinol 2025. DOI · PMID 40031941
  10. Zhao L et al. Tirzepatide for weight reduction in Chinese adults with obesity (SURMOUNT-CN). JAMA 2024;332:551–60. DOI · PMID 38819983
  11. ClinicalTrials.gov trial site lists, read 5 Oct 2026: STEP 1 · STEP 2 · SURMOUNT-1 · SURMOUNT-2
  12. Jarso G, Mahendru S, Dutta A, Sharma R, Megerso A, Mithal A. Magnitude and determinants of weight loss response to GLP-1/GIP receptor agonists in India: a real-world time-to-event analysis. Indian J Endocrinol Metab 2026. DOI · PMID 42238558. Declared interests: none (paper's own declaration).
  13. Chandra KP et al. Real-world evidence of tirzepatide in Indian adults with type 2 diabetes. Cureus 2026. DOI · PMID 41798487
  14. Kapoor N et al. Comparative efficacy and safety of once-weekly semaglutide formulations in Indian adults with obesity (Size Plus study). Cureus 2026. DOI · PMID 41884323. Declared interests: sponsored by Alkem Laboratories; five authors employed by Alkem (paper's own declaration).
  15. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. DOI · PMID 35441470
  16. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024;331:38–48. DOI · PMID 38078870
  17. Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (STEP 1–3). Diabetes Obes Metab 2022;24:94–105. DOI · PMID 34514682
  18. Business Standard, 12 December 2025. "Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles". Link
  19. Business Standard, 13 August 2025. Eli Lilly launches Mounjaro KwikPen in India. Link
  20. ThePrint, 24 June 2025. "Wegovy, the global sensation in obesity management, launched in India". Link
  21. Medical Dialogues, 10 September 2025. Novo Nordisk gets CDSCO panel nod for Rybelsus label update. Link
  22. Atal S, Agrawal C, Gupta R, Sadasivam B. Pharmacological management of obesity: current landscape and emerging therapies. Indian J Pharmacol 2026. DOI · PMID 42683980
  23. Jain SS et al. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 2011;15:99–104. DOI · PMID 21731866
  24. Outlook India, 1 April 2026. Government statement on inspections and GLP-1 prescribing. Link
  25. Medical Dialogues, 10 July 2026. Recalls by Dr Reddy's, Torrent put spotlight on quality standards in India's semaglutide market. Link
  26. Medical Dialogues, 18 April 2026, reporting CDSCO's 10 March 2026 advisory on surrogate advertising and misleading promotion of GLP-1 obesity drugs. Link
  27. Madhu SV et al. Endocrine Society of India (ESI) obesity guideline 2025. Indian J Endocrinol Metab 2025;29:355–65. DOI. Declared interests: none (paper's own declaration).
  28. NICE (UK). Semaglutide for managing overweight and obesity, TA875, recommendation 1.2. Link. Declared interests: some expert advisers declared Novo Nordisk or Eli Lilly payments (NICE register of interests).
  29. Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. J Assoc Physicians India 2009;57:163–70. PMID 19582986
  30. CHEPLAPHARM. Xenical (orlistat 120 mg) prescribing information, DailyMed version effective 9 Jan 2026. US label, not the Indian one (we found no Indian label online). Link
  31. Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS). Diabetes Care 2004;27:155–61. DOI · PMID 14693982
  32. Novo Nordisk. Rybelsus (semaglutide tablets) prescribing information, revised 1/2026. US label: Trial 1 weight results, side-effect rates and the 3 mg starting dose. PDF
  33. Haleon. Alli (orlistat 60 mg) Drug Facts label, DailyMed version of 18 March 2026. US label. Link
  34. US FDA. Questions and answers about FDA's initiative against contaminated weight loss products (content current as of 18 Aug 2021). US. Link
  35. US FDA. Public notification: Detoxi Slim contains hidden drug ingredient (sibutramine). First issued 26 June 2019, updated 14 July 2026. US. Link
  36. Indian pharmacy product listings (Apollo Pharmacy, orlistat 60 mg capsule by Cipla, marked "Prescription drug"), checked 5 Oct 2026. Not linked: we don't link pages that sell medicines.
  37. Press Information Bureau (PIB Research). GLP-1 Drugs: Use, Risks, and Regulation. Government backgrounder, 1 April 2026. PIB
  38. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism): 20–21 April 2023 (tirzepatide: "sold by retail under prescription of Endocrinologist or internal medicine specialists only") and 13–14 February 2024 (semaglutide warning statement). April 2023 · archived copy · February 2024 · archived copy

Last checked 5 Oct 2026 · Next review due 5 Oct 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write